MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Industry, Sector and Symbol:
- Industry: Specialized Health Services
- Sub-Industry: Health Care Services
- Symbol: NYSE:MD
- CUSIP: 58502B10
- Web: www.mednax.com
- Market Cap: $5.07 billion
- Outstanding Shares: 92,360,000
- 50 Day Moving Avg: $59.90
- 200 Day Moving Avg: $65.81
- 52 Week Range: $53.80 - $76.96
Sales & Book Value:
- Trailing P/E Ratio: 16.39
- Foreward P/E Ratio: 13.72
- P/E Growth: 1.05
- Annual Revenue: $3.27 billion
- Price / Sales: 1.55
- Book Value: $29.91 per share
- Price / Book: 1.84
- EBIDTA: $648.78 million
- Net Margins: 10.21%
- Return on Equity: 13.59%
- Return on Assets: 7.06%
- Debt-to-Equity Ratio: 0.73%
- Current Ratio: 1.44%
- Quick Ratio: 1.39%
- Average Volume: 970,022 shs.
- Beta: 0.67
- Short Ratio: 12.96
Frequently Asked Questions for MEDNAX (NYSE:MD)
What is MEDNAX's stock symbol?
MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were MEDNAX's earnings last quarter?
MEDNAX Inc (NYSE:MD) announced its quarterly earnings results on Thursday, May, 4th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.01. The firm had revenue of $835.60 million for the quarter, compared to the consensus estimate of $837.01 million. MEDNAX had a return on equity of 13.59% and a net margin of 10.21%. The company's quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 earnings per share. View MEDNAX's Earnings History.
What guidance has MEDNAX issued on next quarter's earnings?
MEDNAX issued an update on its second quarter earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $0.85-0.89 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.00.
Where is MEDNAX's stock going? Where will MEDNAX's stock price be in 2017?
9 brokers have issued twelve-month price targets for MEDNAX's stock. Their forecasts range from $58.00 to $72.00. On average, they anticipate MEDNAX's share price to reach $65.57 in the next twelve months. View Analyst Ratings for MEDNAX.
What are analysts saying about MEDNAX stock?
Here are some recent quotes from research analysts about MEDNAX stock:
- 1. According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (4/27/2017)
- 2. Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)
Are investors shorting MEDNAX?
MEDNAX saw a decrease in short interest during the month of April. As of April 28th, there was short interest totalling 7,120,627 shares, a decrease of 24.9% from the April 13th total of 9,480,171 shares. Based on an average daily volume of 1,584,427 shares, the days-to-cover ratio is presently 4.5 days. Approximately 7.8% of the company's shares are short sold.
Who are some of MEDNAX's key competitors?
Some companies that are related to MEDNAX include Omnicare (OCR), HealthSouth Corp (HLS), Acadia Healthcare Company (ACHC), AMN Healthcare Services (AMN), Phibro Animal Health Corp (PAHC), Tivity Health (TVTY), U.S. Physical Therapy (USPH), The Providence Service (PRSC), Hanger (HGR), AAC Holdings (AAC), Envision Healthcare Corp (AMSG) and Intrepid Healthcare Services (IPCM).
Who are MEDNAX's key executives?
MEDNAX's management team includes the folowing people:
- Cesar L. Alvarez, Chairman of the Board
- Joseph M. Calabro, President, Chief Operating Officer
- Roger J. Medel M.D., Chief Executive Officer, Director
- Vivian Lopez-Blanco, Chief Financial Officer, Treasurer
- David A. Clark, President - MEDNAX National Medical Group Division
- John C. Pepia, Senior Vice President, Chief Accounting Officer
- Dominic J. Andreano, Senior Vice President, General Counsel, Secretary
- Manuel Kadre, Lead Independent Director
- Karey D. Barker, Independent Director
- Waldemar A. Carlo M.D., Independent Director
Who owns MEDNAX stock?
MEDNAX's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.87%), Vanguard Group Inc. (8.10%), FMR LLC (5.73%), Longview Partners Guernsey LTD (4.91%), State Street Corp (3.19%) and Nordea Investment Management AB (2.80%). Company insiders that own MEDNAX stock include Cesar L Alvarez, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos, Roger Md Medel and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.
Who sold MEDNAX stock? Who is selling MEDNAX stock?
MEDNAX's stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Mawer Investment Management Ltd., TimesSquare Capital Management LLC, Goldman Sachs Group Inc., Handelsbanken Fonder AB, Columbia Wanger Asset Management LLC, Bank of Montreal Can and Teachers Advisors LLC. Company insiders that have sold MEDNAX stock in the last year include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX.
Who bought MEDNAX stock? Who is buying MEDNAX stock?
MEDNAX's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Schroder Investment Management Group, Longview Partners Guernsey LTD, Victory Capital Management Inc., Fiduciary Management Inc. WI, Vanguard Group Inc., Dimensional Fund Advisors LP and Morgan Stanley. Company insiders that have bought MEDNAX stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.
How do I buy MEDNAX stock?
Shares of MEDNAX can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEDNAX's stock price today?
MarketBeat Community Rating for MEDNAX (NYSE MD)MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of MEDNAX stock can currently be purchased for approximately $54.89.
Earnings History for MEDNAX (NYSE:MD)Earnings History by Quarter for MEDNAX (NYSE MD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/4/2017||Q1 2017||$0.74||$0.75||$837.01 million||$835.60 million||View||N/A|
|2/7/2017||Q416||$1.06||$1.00||$842.15 million||$831.00 million||View||Listen|
|10/27/2016||Q316||$1.05||$1.09||$821.18 million||$828.00 million||View||Listen|
|7/28/2016||Q216||$1.07||$1.03||$775.68 million||$772.00 million||View||Listen|
|4/28/2016||Q116||$0.86||$0.87||$741.49 million||$752.60 million||View||Listen|
|2/4/2016||Q415||$1.10||$1.13||$748.02 million||$742.00 million||View||Listen|
|10/29/2015||Q315||$0.97||$1.10||$730.63 million||$722.30 million||View||Listen|
|7/30/2015||Q215||$0.88||$0.97||$677.02 million||$676.60 million||View||Listen|
|4/30/2015||Q115||$0.71||$0.72||$641.24 million||$639.40 million||View||Listen|
|1/29/2015||Q414||$0.87||$0.89||$637.90 million||$651.00 million||View||Listen|
|10/30/2014||Q314||$0.85||$0.86||$619.61 million||$627.00 million||View||Listen|
|7/31/2014||Q214||$0.78||$0.79||$603.00 million||$595.54 million||View||Listen|
|5/1/2014||Q114||$0.63||$0.63||$574.80 million||$566.00 million||View||Listen|
|1/30/2014||Q4||$0.75||$0.20||$555.30 million||$567.00 million||View||Listen|
|10/31/2013||Q313||$1.48||$1.52||$556.63 million||$555.00 million||View||Listen|
|7/30/2013||Q2 2013||$1.36||$1.37||$533.39 million||$529.18 million||View||Listen|
|5/2/2013||Q1 2013||$1.09||$1.10||$504.24 million||$502.70 million||View||Listen|
|1/31/2013||Q4 2012||$1.30||$1.32||$473.70 million||$471.30 million||View||Listen|
|11/1/2012||Q312||$1.28||$1.32||$470.60 million||$473.10 million||View||N/A|
Earnings Estimates for MEDNAX (NYSE:MD)
2017 EPS Consensus Estimate: $3.95
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for MEDNAX (NYSE:MD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MEDNAX (NYSE:MD)
Insider Ownership Percentage: 2.40%Insider Trades by Quarter for MEDNAX (NYSE:MD)
Institutional Ownership Percentage: 99.16%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/5/2017||Manuel Kadre||Director||Buy||21,704||$55.79||$1,210,866.16|| |
|5/5/2017||Vivian Lopez-Blanco||CFO||Sell||7,778||$55.82||$434,167.96|| |
|2/23/2017||Enrique Sosa||Director||Sell||10,668||$69.65||$743,026.20|| |
|2/17/2017||Vivian Lopez-Blanco||CFO||Sell||15,164||$70.01||$1,061,631.64|| |
|2/16/2017||Dominic J Andreano||SVP||Sell||6,000||$69.59||$417,540.00|| |
|2/16/2017||John C Pepia||Insider||Sell||2,500||$69.58||$173,950.00|| |
|2/16/2017||Paul G Gabos||Director||Sell||21,336||$69.63||$1,485,625.68|| |
|2/10/2017||Md Pascal J Goldschmidt||Director||Sell||25,294||$67.82||$1,715,439.08|| |
|2/9/2017||Md Carlo A Waldemar||Director||Sell||5,334||$67.90||$362,178.60|| |
|1/17/2017||Vivian Lopez-Blanco||CFO||Sell||10,000||$70.95||$709,500.00|| |
|12/7/2016||Md Pascal J Goldschmidt||Director||Buy||2,100||$66.52||$139,692.00|| |
|9/14/2016||Md Pascal J Goldschmidt||Director||Sell||1,500||$65.01||$97,515.00|| |
|6/13/2016||Dominic J Andreano||SVP||Sell||3,922||$68.80||$269,833.60|| |
|6/8/2016||Md Carlo A Waldemar||Director||Sell||5,334||$70.50||$376,047.00|| |
|6/7/2016||Karl B Wagner||Insider||Sell||27,482||$68.45||$1,881,142.90|| |
|6/1/2016||Joseph M Calabro||COO||Sell||28,347||$67.78||$1,921,359.66|| |
|6/1/2016||Michael D Stanley||Insider||Sell||14,778||$67.78||$1,001,652.84|| |
|5/16/2016||Dominic J Andreano||SVP||Sell||3,000||$68.53||$205,590.00|| |
|5/2/2016||Vivian Lopez-Blanco||CFO||Sell||9,350||$71.22||$665,907.00|| |
|3/11/2016||Md Pascal J Goldschmidt||Director||Sell||3,100||$65.00||$201,500.00|| |
|2/29/2016||Paul G Gabos||Director||Sell||10,668||$67.15||$716,356.20|| |
|12/11/2015||Md Pascal J. Goldschmidt||Director||Sell||5,250||$70.99||$372,697.50|| |
|9/8/2015||Cesar L. Alvarez||Director||Sell||10,668||$81.00||$864,108.00|| |
|8/27/2015||Roger Md Medel||CEO||Sell||100,000||$80.27||$8,027,000.00|| |
|6/8/2015||Karl B Wagner||Insider||Sell||37,820||$70.28||$2,657,989.60|| |
|6/3/2015||Joseph M Calabro||COO||Sell||108,071||$70.51||$7,620,086.21|| |
|3/9/2015||Md Pascal J Goldschmidt||Director||Sell||8,500||$71.25||$605,625.00|| |
|2/26/2015||Roger Md Medel||CEO||Sell||100,000||$71.61||$7,161,000.00|| |
|2/20/2015||Md Carlo A Waldemar||Director||Sell||10,668||$71.50||$762,762.00|| |
|2/6/2015||Dominic J Andreano||SVP||Sell||3,200||$70.75||$226,400.00|| |
|2/6/2015||Vivian Lopez-Blanco||CFO||Sell||8,250||$69.95||$577,087.50|| |
|2/2/2015||Paul G Gabos||Director||Sell||17,584||$68.07||$1,196,942.88|| |
|1/30/2015||William C Hawk||COO||Sell||3,598||$68.50||$246,463.00|| |
|11/14/2014||Roger Md Medel||CEO||Sell||51,290||$62.59||$3,210,241.10|| |
|11/13/2014||Roger Md Medel||CEO||Sell||63,440||$62.55||$3,968,172.00|| |
|11/7/2014||Roger Md Medel||CEO||Sell||128,833||$62.60||$8,064,945.80|| |
|11/5/2014||Roger Md Medel||CEO||Sell||169,845||$62.60||$10,632,297.00|| |
|11/4/2014||Roger Md Medel||CEO||Sell||15,052||$62.52||$941,051.04|| |
|11/3/2014||Roger Md Medel||CEO||Sell||10,881||$62.52||$680,280.12|| |
|10/31/2014||Roger Md Medel||CEO||Sell||61,592||$62.58||$3,854,427.36|| |
|10/30/2014||Karl B Wagner||Insider||Sell||40,000||$62.50||$2,500,000.00|| |
|10/30/2014||Vivian Lopez-Blanco||CFO||Sell||8,800||$60.00||$528,000.00|| |
|7/30/2014||Karl B Wagner||Insider||Sell||80,000||$60.00||$4,800,000.00|| |
|6/10/2014||Dominic J Andreano||SVP||Sell||2,252||$58.48||$131,696.96|| |
|6/6/2014||Karl B Wagner||Insider||Sell||44,596||$58.53||$2,610,203.88|| |
|6/5/2014||William C Hawk||COO||Sell||6,911||$57.66||$398,488.26|| |
|6/2/2014||David A Clark||COO||Sell||16,230||$57.00||$925,110.00|| |
|6/2/2014||Michael D Stanley||Insider||Sell||18,006||$57.00||$1,026,342.00|| |
|5/9/2014||Karl Wagner||Insider||Sell||79,524||$57.09||$4,540,025.16|| |
|5/9/2014||Md Pascal Goldschmidt||Director||Sell||30,000||$57.11||$1,713,300.00|| |
|5/8/2014||Joseph Calabro||COO||Sell||137,500||$57.06||$7,845,750.00|| |
|2/20/2014||Dominic Andreano||SVP||Sell||3,000||$61.00||$183,000.00|| |
|2/10/2014||Joseph Calabro||COO||Sell||150,000||$55.55||$8,332,500.00|| |
|2/10/2014||Md Carlo Waldemar||Director||Sell||10,668||$55.40||$591,007.20|| |
|11/7/2013||Enrique Sosa||Director||Sell||5,334||$107.00||$570,738.00|| |
|11/7/2013||Karl Wagner||Insider||Sell||1,800||$107.60||$193,680.00|| |
|9/11/2013||William C Hawk||COO||Sell||3,162||$100.62||$318,160.44|| |
|9/10/2013||Dominic J Andreano||SVP||Sell||3,718||$99.63||$370,424.34|| |
|8/7/2013||Karl Wagner||Insider||Sell||25,000||$98.01||$2,450,250.00|| |
|8/2/2013||Joseph M Calabro||COO||Sell||36,154||$98.57||$3,563,699.78|| |
|6/3/2013||David A Clark||COO||Sell||8,645||$91.01||$786,781.45|| |
|6/3/2013||Michael D Stanley||Insider||Sell||8,906||$91.01||$810,535.06|| |
Headline Trends for MEDNAX (NYSE:MD)
Latest Headlines for MEDNAX (NYSE:MD)
MEDNAX (MD) Chart for Tuesday, May, 30, 2017